Clinical trial
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or…
NCT02631070 · Celgene, Industry · Completed
Key facts
| NCT number | NCT02631070 |
|---|---|
| Title | A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes |
| Official title | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell… |
| Acronym | MEDALIST |
| Lead sponsor | Celgene, Industry |
| Collaborators | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug, Other |
| Interventions | Luspatercept, Placebo |
| Enrollment | 229 |
| Start date | Feb 9, 2016 |
| Primary completion | Jun 18, 2019 |
| Completion | Nov 26, 2020 |
| First posted | Dec 15, 2015 |
| Last update posted | Dec 17, 2021 |
| Countries | Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: